AMENDED AND RESTATED MATERIAL TRANSFER AND RESEARCH AGREEMENTMaterial Transfer and Research Agreement • September 29th, 2023 • AIM ImmunoTech Inc. • Biological products, (no disgnostic substances) • New York
This Amended and Restated Material Transfer and Research Agreement (“Agreement”) is made as of September 20, 2023 (“Effective Date”), by and between AIM IMMUNOTECH, INC., a Delaware Corporation with a principal place of business located at 2117 SW Highway 484, Ocala, Florida 34473 (“AIM”), and Roswell Park Cancer Institute CORPORATION d/b/a roswell park comprehensive cancer centeR, a New York public benefit corporation with a principal place of business located at Elm and Carlton Streets, Buffalo, NY 14263 (“Institute”). AIM and Institute shall be referred to individually as a “party” and together as the “parties.”
EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL ANDMaterial Transfer and Research Agreement • August 14th, 2020 • AIM ImmunoTech Inc. • Biological products, (no disgnostic substances) • New York
This Material Transfer and Research Agreement (the “Agreement”) is made as of May 15, 2020, (“Effective Date”) by and between AIM ImmunoTech, Inc. (“AIM”), located at 2117 SW Highway 484, Ocala, FL 34473, and University of Rochester (“Rochester”), having a business address at the Office of Research & Project Administration 518 Hylan Building, Box 270140, Rochester, NY 14627. AIM and Rochester shall be referred to individually as a “party” and together as the “parties.”
EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. MATERIAL TRANSFER AND RESEARCH AGREEMENTMaterial Transfer and Research Agreement • May 30th, 2023 • AIM ImmunoTech Inc. • Biological products, (no disgnostic substances) • New York
This Agreement is made as of May 8, 2023 (“Effective Date”) by and between AIM IMMUNOTECH INC. (“AIM”), a corporation incorporated under the laws of Delaware, having an Offices at 2117 SW Hwy 484 Ocala Fl 34473 as the supplier of the experimental drug Ampligen® and Japanese National Institute of Infectious Disease (“NIID”) with its address at Toyama 1-23-1, Shinjuku-ku Tokyo 162-8640, Japan, (NIID”). AIM and NIID shall be referred to individually as a “Party” and together as the “Parties.”
MATERIAL TRANSFER AND RESEARCH AGREEMENTMaterial Transfer and Research Agreement • April 6th, 2020 • AIM ImmunoTech Inc. • Biological products, (no disgnostic substances) • New York
This Material Transfer and Research Agreement (“Agreement”) is made as of March [correct date], 2020 (“Effective Date”) by and between AIM ImmunoTech, Inc. (“AIM”), located at 2117 SW Highway 484, Ocala, FL 34473, USA, and Shenzhen Smoore Technology Limited (“Smoore”), located at Block 16th, Dongcai Industry Park, Gushu Village, Xixiang Town, Bao’an District Shenzhen, People’s Republic of China (“PRC”). AIM and Smoore shall be referred to individually as a “Party” and together as the “Parties”.
